EP4353734A1 - Procédé de purification d'une composition d'anticorps - Google Patents

Procédé de purification d'une composition d'anticorps Download PDF

Info

Publication number
EP4353734A1
EP4353734A1 EP22807406.8A EP22807406A EP4353734A1 EP 4353734 A1 EP4353734 A1 EP 4353734A1 EP 22807406 A EP22807406 A EP 22807406A EP 4353734 A1 EP4353734 A1 EP 4353734A1
Authority
EP
European Patent Office
Prior art keywords
antibody
media
glycosylation
chromatography
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22807406.8A
Other languages
German (de)
English (en)
Inventor
Takayuki Yoshimori
Stefan IARUSSO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiome Bioscience Inc
Original Assignee
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc filed Critical Chiome Bioscience Inc
Publication of EP4353734A1 publication Critical patent/EP4353734A1/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the present invention relates to a production method for an antibody composition.
  • the present invention relates to a purification method for an antibody composition with reduced levels of isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region.
  • Antibody drugs comprising a monoclonal antibody as an active ingredient are expected as one of the molecular targeted drugs based on the high binding affinity and binding specificity of an antibody molecule for its antigen, and their research and development have progressed. Antibody drugs are indispensable for the treatment of various diseases including cancers and autoimmune diseases, and nearly 100 of products have now been approved and used in the world (Non-patent Document 1, Non-patent Document 2). Expectations remain high for the development of novel antibody drugs satisfying unmet medical needs, and it is further expected that many new antibody drugs will be investigated and developed.
  • An antibody has an N-linked sugar chain at the Asn residue at position 297 (Asn297) in a glycosylation consensus region (Asn297-X-Ser/Thr, wherein X is an amino acid other than Pro) present in the heavy chain Fc region.
  • a sugar chain present in this glycosylation consensus region is known to contribute to properties as an antibody molecule, such as biological activity, pharmacokinetics in blood, safety and so on (Non-patent Document 3, Non-patent Document 4).
  • ADCC antibody-dependent cellular cytotoxicity
  • Fuc residue core fucose
  • GlcNAc N-acetylglucosamine
  • Non-patent Document 3 the antineoplastic agent Cetuximab produced in SP2/0 cells was confirmed to have an N-linked sugar chain linked to its Fab region.
  • Non-patent Document 6 various reports have been made on glycosylation isomers.
  • Glycosylation isomers are known to have the potential to affect various antibody properties such as biological activity (Non-patent Document 10, Non-patent Document 11), immunogenicity (Non-patent Document 8, Non-patent Document 10), blood half-life (Non-patent Document 9), etc.
  • a sugar chain linked near an Fab region or a CDR region will raise a concern for the risk of reduced biological activity.
  • glycosylation isomers i.e., antibodies having sugar chains linked to sites other than the glycosylation consensus region have a concern for safety such as immunogenicity, etc.
  • Non-patent Document 12 When biological activity is greatly reduced and/or immunogenicity is greatly increased upon attachment of sugar chains to sites other than the glycosylation consensus region, there will arise a negative effect undesirable for ingredients of antibody drugs, so that these glycosylation isomers are regarded as product-related impurities. Such product-related impurities are not desired to be contained as ingredients of drugs, and are desired to be removed as much as possible, also from a regulatory perspective (Non-patent Document 12).
  • Glycosylation isomers having sugar chains linked to antibody regions e.g., Fab or CDR
  • antibody regions e.g., Fab or CDR
  • Fab or CDR antibody regions
  • Non-patent Document 9 Non-patent Document 9
  • antibodies having sugar chains linked to their Fab region were analyzed by hydrophobic interaction chromatography (HIC) (Non-patent Document 13).
  • Non-patent Document 14 discloses the usefulness of separation performance for many antibodies, but it does not suggest at all that glycosylation isomers can be separated by HIC-based purification techniques.
  • glycosylation isomers can merely be evaluated for their glycosylation status at the analytical level, and there has been no method for separating and removing glycosylation isomers of an antibody to produce an antibody composition in an amount sufficient to be provided as a drug.
  • such an antibody composition has not been known.
  • Non-patent Document 15 Non-patent Document 16
  • This technique is designed to use Concanavalin A as a ligand and has also been found to have high separation properties.
  • this technique is affinity-based separation and is not suitable for the production of drugs because of using natural substances. Thus, there is no case where this technique was applied to the production of antibody drugs.
  • Non-patent Document 17 As to techniques other than those mentioned above, it is known that sugar chains are removed by enzymatic treatment (Non-patent Document 17). However, in terms of safety, problems may arise from the separation and removal of enzymes and their origin, etc. Thus, this technique is difficult to use as a production technique for drugs. In the enzymatic removal of antibody sugar chains, it is also impossible to distinguish between sugar chains in glycosylation consensus and non-consensus regions.
  • the anti-hDLK-1 antibody shown in Patent Document 4 is an antibody whose antitumor activity is expected to be promising.
  • the present invention aims to provide a method for removing glycosylation isomers in antibody drugs.
  • the present invention aims to obtain a more effective and safer purified composition of anti-hDLK-1 antibody.
  • the inventors of the present invention have made an effort to separate glycosylation isomers and purify non-glycosylation isomers for the anti-hDLK-1 antibody shown in Patent Document 4 by using the newly found method for reducing glycosylation isomers.
  • Glycosylation isomers having sugar chains near CDRs in an antibody may affect the binding activity of the antibody, but the degree of reduction in the activity is also related to the size and positions of sugar chains linked; and hence there is also a possibility that these glycosylation isomers will not affect the activity.
  • the inventors of the present invention have found that glycosylation isomers completely lose activity and therefore become "impurities" in drugs.
  • the inventors of the present invention have succeeded in identifying glycosylation isomers as new impurities in a crude anti-hDLK-1 antibody product, and have enabled the removal of these glycosylation isomers to thereby achieve the provision of a more effective and safer purified composition of anti-hDLK-1 antibody.
  • the present invention relates to (1) to (27) shown below.
  • the present invention enables the reduction or removal of glycosylation isomers having sugar chains attached to sites other than the glycosylation consensus region in an antibody.
  • the present invention enables the provision of an antibody composition for medical use with reduced content of glycosylation isomers.
  • the thus purified high-purity antibody composition with reduced levels of glycosylation isomers can be formulated into pharmaceutical formulations with higher purity.
  • the present invention enables the provision of an antibody composition for medical use free from glycosylation isomers.
  • the thus obtained antibody composition can be provided as a composition whose active pharmaceutical ingredient is of very high purity, i.e., as a pharmaceutical composition excellent in efficacy and safety.
  • the purified composition of anti-hDLK-1 antibody purified in the present invention is free from inactive impurities, i.e., glycosylation isomers, and therefore can be provided as a pharmaceutical composition excellent in efficacy and safety.
  • glycosylation consensus sequence is intended to mean an amino acid sequence represented by Asn-X-Ser/Thr (wherein X is an amino acid other than Pro), regardless of the position of this sequence in an antibody and the position where Asn is present.
  • Fc region glycosylation consensus region or “glycosylation consensus region” refers to a glycosylation consensus sequence usually comprising Asn297 present in the antibody Fc portion (typically, Asn297-X-Ser/Thr (wherein X is an amino acid other than Pro)).
  • a nucleotide sequence encoding such a glycosylation consensus sequence or glycosylation consensus region includes any sequences as long as they each encode this amino acid sequence.
  • glycosylation isomers is intended to mean antibodies having sugar chains attached to amino acids other than those in the glycosylation consensus region.
  • Sugar chains attached to amino acids other than those in the glycosylation consensus region are referred to as “non-consensus sugar chains.”
  • regions to which non-consensus sugar chains are linked include an Fab region, an antigen-binding Fv (variable) region, a complementarity determining region (CDR), an Fc region except for the glycosylation consensus region, and a fusion sequence portion in a fusion antibody, typically a CDR region.
  • sugar chain linkage mode of non-consensus sugar chains to amino acids other than those in the glycosylation consensus region they may be N-linked sugar chains to the glycosylation consensus sequence Asn-X-Ser/Thr (wherein X is an amino acid other than Pro) or O-linked sugar chains to Ser or Thr.
  • the structure of an antibody molecule is generally a heterotetramer and is formed from two sets of two identical polypeptide chains joined together. Thus, linkage sites for non-consensus sugar chains are present at multiples of 2 per antibody molecule in theory.
  • a crude antibody product to be purified in the present invention may contain antibodies having one or more non-consensus sugar chains.
  • the number of non-consensus sugar chains linked per antibody molecule may be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more.
  • the number of non-consensus sugar chains linked to any one of these polypeptide chains may be 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more.
  • the ratio of sugar chains linked to regions to which non-consensus sugar chains are linkable in a crude antibody product i.e., the ratio of glycosylation isomers present in a crude antibody product may be 0.1% or more and 200% or less per antibody molecule, relative to the case where non-consensus sugar chains are completely linked to one of the "combinations of heavy and light chains" in one antibody molecule or a structure equivalent thereto, which is set to 100%.
  • This ratio is usually 1% or more and 50% or less in a crude antibody product in need of applying the method of the present invention. 200% intended here means that non-consensus sugar chains are linked to both of the pairing "combinations of heavy and light chains" (i.e., two sites) in one antibody molecule.
  • the term "antibody” includes not only a full-length antibody, but also an antibody fragment, and a fusion product of a full-length antibody or an antibody fragment with another substance. Examples include a mouse antibody, a mouse-human chimeric antibody, a humanized antibody, a human antibody, and their amino acid variants, addition variants, deletion variants, substitution variants and sugar chain variants, etc.
  • the immunoglobulin class of an antibody is not limited in any way, and may be any of the immunoglobulin classes (isotypes) IgG, IgM, IgA, IgE, IgD and IgY, preferably IgG.
  • the antibody of the present invention may be of any subclass (IgG1, IgG2, IgG3 or IgG4).
  • An antibody fragment is preferably an antigen-binding fragment, including F(ab') 2 , Fab', Fab, Fabs, single-chain Fv (hereinafter referred to as "scFv"), (tandem) bispecific single-chain Fv (sc(Fv) 2 ), single-chain triple body, nanobody, divalent V H H, pentavalent V H H, minibody, (double-chain) diabody, tandem diabody, bispecific tribody, bispecific bibody, dual affinity retargeting molecule (DART), triabody (or tribody), tetrabody (or [sc(Fv) 2 ] 2 , or (scFv-SA) 4 ), disulfide-stabilized Fv (hereinafter referred to as "dsFv”), compact IgG, heavy chain antibody
  • dsFv disulf
  • the antibody intended herein means an anti-hDLK-1 antibody whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 10 or 12. It is preferably an anti-hDLK-1 antibody whose heavy chain has an amino acid sequence selected from SEQ ID Nos: 4, 8, 16, 20, 24, 28, 32 and 36, and whose light chain has the amino acid sequence shown in SEQ ID NO: 12.
  • An antibody composition containing glycosylation isomers to be purified is herein referred to as a "crude antibody product.”
  • Any crude antibody product may be used as long as it contains glycosylation isomers.
  • Examples of a crude antibody product include a biological composition (e.g., plasma) or a treated product thereof, and a culture solution (which may be a culture supernatant; the same applies hereinafter) of antibody gene-transfected transformed cells or a treated product thereof.
  • a biological composition may be exemplified by a composition comprising antibodies obtained from a transgenic non-human animal or a plant, etc.
  • Transformed cells are not limited in any way as long as they allow glycosylation, and specific examples include cell lines of animal, plant or yeast origin, which have the property of allowing glycosylation, and more specific examples include Chinese hamster ovary cells (CHO cells), mouse myeloma cells (NS0 cells, SP2/0 cells), rat myeloma cells (YB2/0 cells, IR983F cells), Syrian hamster kidney-derived BHK cells, human fetal kidney-derived 293 cells, human myeloma cells (Namalwa cells), embryonic stem cells, or antibody gene-transfected fertilized eggs, etc.
  • CHO cells Chinese hamster ovary cells
  • NS0 cells, SP2/0 cells mouse myeloma cells
  • YB2/0 cells rat myeloma cells
  • IR983F cells Chinese hamster kidney-derived BHK cells
  • human fetal kidney-derived 293 cells human myeloma cells
  • embryonic stem cells or antibody
  • CHO K1, CHO DG44 and CHO S cell lines, and their derived cell lines, etc. Palsson et al., Nature Biotechnology 31(8), 759-765, 2013 ).
  • a crude antibody product may be obtained as a culture solution.
  • examples include a serum-containing medium, a medium containing no animal-derived component such as serum albumin or serum fraction, a serum-free medium and a protein-free medium, and preferred for use is a serum-free medium, a medium containing no animal-derived material, a protein-free medium, or a completely chemical synthetic medium.
  • the above crude antibody product it is also possible to use a biological composition or a culture solution treated by filtration, salting-out, one or more chromatography techniques, pH adjustment, buffer replacement, concentration, dilution, etc., or an intermediate composition derived from the biological composition or culture solution during purification or other operations.
  • an intermediate composition derived during purification it is possible to use even a solution obtained after any unit operations required to construct the production process of antibody drugs. For example, it is desired to use a composition obtained after Protein A affinity chromatography, after cation exchange chromatography, after anion exchange chromatography, after buffer replacement, after low pH treatment, or after filtration, etc.
  • N-linked sugar chains the possible presence of glycosylation isomers can be estimated from the amino acid sequence or gene sequence of the antibody.
  • the positions for sugar chain linkages can be estimated by peptide mapping and mass spectrometry on the antibody. More conveniently, a peptide-N-glycosidase (PNGase)-treated antibody and a non-treated antibody may be compared by SDS polyacrylamide gel electrophoresis (SDS-PAGE), whereby sugar chain linkages can be observed as changes in protein electrophoretic bands.
  • PNGase peptide-N-glycosidase
  • SDS-PAGE SDS polyacrylamide gel electrophoresis
  • antibody drugs are required to have a consistency in the content of antibody isomers contained therein, and are required to minimize product-related impurities (the ICH Q6B guideline).
  • a therapeutic or prophylactic antibody include an antibody neutralizing the activity of a ligand through binding to the ligand, an antibody neutralizing the binding of a ligand through binding to its receptor on the cell surface, and an antibody exerting cytotoxic activity on cells themselves through binding to their cell surface.
  • diagnostic antibody include an antibody binding to a ligand or a receptor on the cell surface.
  • the cytotoxic activity on cells may be exemplified by antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis activity, etc.
  • the technique of the present invention may also be used for antibody derivatives as long as they have sugar chains, as exemplified by chemically modified antibodies (e.g., antibody-drug conjugates, radioisotope-labelled antibodies), fusion antibodies with cytokines, etc., and multi-specific antibodies ( Nature, 580(16), 330-338 (2020 )), etc.
  • this method can be used in the purification of antibodies against protein antigens (preferably protein antigens of human origin), including CD3, EGF receptor, CD20, RS virus, TNF ⁇ , CD25, IL-6 receptor, CD33, VEGF, IgE, complement C5, IL-12, IL-23, IL-1 ⁇ , RANKL, CCR4, HER2, CD30, IL-5, IL-5 receptor, ⁇ 4 integrin, ⁇ 4 ⁇ 7 integrin, PD-1, CD52, IL-17, IL-17A, IL-17 receptor, CTLA-4, PCSK9, SLAMF7, BlyS, CD38, PD-L1, IL-4 ⁇ receptor, CD22, CD23, factor Ixa, factor X, CD19, sclerostin, DLK-1, etc.
  • protein antigens preferably protein antigens of human origin
  • a fusion protein examples include a soluble TNF receptor Fc fusion protein, a CTLA4-modified Fc fusion protein, a Fc-TPOR agonist peptide fusion protein, a VEGF receptor-Fc fusion protein, etc. This method can be used in the purification of any of these antibodies or fusion proteins, etc.
  • an anti-DLK-1 antibody is a humanized anti-human DLK-1 antibody as appears in Patent Document 4 ( WO2014/054820 ) given above, as exemplified by an antibody comprising a heavy chain having an amino acid sequence selected from SEQ ID Nos: 2, 4, 6, 8, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36 (particularly a heavy chain having any of these amino acid sequences as a variable region; the same applies hereinafter in this paragraph), and a light chain having the amino acid sequence shown in SEQ ID NO: 10 or 12 (particularly a light chain having any of these amino acid sequences as a variable region; the same applies hereinafter in this paragraph), and preferred is an antibody comprising a heavy chain having an amino acid sequence selected from SEQ ID NO: 4, 8, 16, 20, 24, 28, 32 and 36, and a light chain having the amino acid sequence shown in SEQ ID NO: 12.
  • Such a humanized anti-human DLK-1 monoclonal antibody has a glycosylation
  • Tables 1 and 2 below contain the full-length sequence of the anti-human DLK-1 antibody shown in Patent Document 4 ( WO2014/054820 ) given above (each underlined section represents a signal sequence, and the underlined sequence is not contained in a mature protein).
  • N in the boxed NSS sequence serves as a glycosylation consensus sequence.
  • DLK-1 antibodies having sequences similar to the sequence of this anti-DLK-1 antibody also have the same possibility.
  • This method is useful as a method for removing or reducing glycosylation isomers from such a crude antibody product containing glycosylation isomers.
  • the amino acid sequences of the H chain of HuBA-1-3D-1, the H chain of HuBA-1-3D-2, the H chain of HuBA-1-3D-1 A24G, the H chain of HuBA-1-3D-2 A24G, the H chain of HuBA-1-3D-1 T73K, the H chain of HuBA-1-3D-2 T73K, the H chain of HuBA-1-3D-1 A24G/T73K, the H chain of HuBA-1-3D-2 A24G/T73K, and the L chain of HuBA-1-3D given in the tables below are shown in SEQ ID Nos: 38, 42, 46, 50, 54, 58, 62, 66 and 70, respectively, in this order.
  • amino acid sequences of mature proteins produced upon removal of signal sequences from the above sequences are shown in SEQ ID Nos: 40, 44, 48, 52, 56, 60, 64, 68 and 72, respectively, in this order.
  • H chain refers to a heavy chain
  • L chain refers to a light chain.
  • the amino acid sequence of CDR1 is "DYAMH” (SEQ ID NO: 73)
  • the amino acid sequence of CDR2 is "VISTYYGNTNYNQKFKG” (SEQ ID NO: 74)
  • the amino acid sequence of CDR3 is "GGLREYYYAMDY” (SEQ ID NO: 75).
  • the amino acid sequence of CDR1 is "KSSQSLLNSSNQKNYLA” (SEQ ID NO: 76)
  • the amino acid sequence of CDR2 is “FASTRES” (SEQ ID NO: 77)
  • the amino acid sequence of CDR3 is "QQHYSTPPT” (SEQ ID NO: 78).
  • the antibody of the present invention may be an antibody having all or some of these CDRs. It should be noted that these CDR sequences were according to the definition of Kabat et al. (Sequences of Proteins of Immunological Interests, Fifth edition, NIH Publication No.91-3242, U.S. Department of Health and Human Services, 1991 ).
  • VH refers to a heavy chain variable region
  • VL refers to a light chain variable region
  • An antibody composition whose glycosylation isomer content is reduced (herein referred to as a "purified antibody composition") when compared to a crude antibody product can be obtained when the crude antibody product containing glycosylation isomers is used as a starting material and subjected to conventional chromatography.
  • the present invention relates to a purification method for a crude antibody product, said method comprising: loading the crude antibody product on conventional chromatography to allow an antibody having no sugar chains attached to sites other than the Fc region glycosylation consensus region to be adsorbed to the media; and treating the media with an eluent to thereby elute the antibody adsorbed to the media to obtain a purified antibody composition, wherein the content of glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region in the resulting purified antibody composition is reduced when compared to the crude antibody product before being subjected to purification.
  • hydrophobic interaction chromatography media As a media for use in conventional chromatography, it is possible to use a hydrophobic interaction chromatography media, a hydrophobic chromatography media, or a mixed-mode chromatography media (also referred to as a multi-mode chromatography media, preferably a mixed-mode chromatography media having the nature of hydrophobic chromatography).
  • a hydrophobic interaction chromatography media As a media for use in conventional chromatography, it is possible to use a hydrophobic interaction chromatography media, a hydrophobic chromatography media, or a mixed-mode chromatography media (also referred to as a multi-mode chromatography media, preferably a mixed-mode chromatography media having the nature of hydrophobic chromatography).
  • a mixed-mode chromatography media also referred to as a multi-mode chromatography media, preferably a mixed-mode chromatography media having the nature of hydrophobic chromatography.
  • a base substrate may be attached with hydrophobic functional groups such as a methyl group, an ethyl group, a propyl group, a butyl group, an octyl group, a hexyl group, a propylene glycol group, a phenyl group, an alkylphenyl group, a benzyl group, and an alkylbenzyl group, etc.
  • hydrophobic functional groups and ion-exchangeable functional groups may be mixed in any ratio.
  • N-benzyl-N-methylethanolamine and so on may be used as functional groups.
  • cation-exchangeable functional groups include CM (carboxymethyl, -O-CH 2 -COOH), SP (sulfopropyl, -O-C 3 H 6 -SO 3 H) and so on, while representative examples of anion-exchangeable functional groups include DEAE (diethylaminoethy, -O-C 2 H 4 -N-(C 2 H 5 ) 2 ), QAE (quaternized aminoethyl or diethyl-(2-hydroxypropyl)-aminoethyl, -O-C 2 H 4 -N-(C 2 H 5 ) 2 (CH 2 -CH(OH)-CH 2 )) and so on, and these functional groups may be used.
  • Examples of a substrate for the media include cellulose, Sephadex, crosslinked agarose, polyacrylamide, methacrylate and various synthetic polymers.
  • the media may or may not be porous, and either may be used.
  • Another form of a mixed-mode chromatography media may be exemplified by those having functional groups such as calcium phosphate, like hydroxyapatite (Ca10(PO 4 ) 6 (OH) 2 ) or fluoroapatite (Ca 10 (PO 4 ) 6 F 2 ).
  • a chromatography media may be obtained as a commercially available product and used. Specific examples include media such as Butyl-Sepharose ® 4 Fast Flow (average particle size: 90 ⁇ m), Butyl-S Sepharose 6 Fast Flow (average particle size: 90 ⁇ m), Octyl Sepharose ® 4 Fast Flow (average particle size: 90 ⁇ m), Phenyl Sepharose ® 6 Fast Flow (high sub) (average particle size: 90 ⁇ m), Phenyl Sepharose ® 6 Fast Flow (low sub) (average particle size: 90 ⁇ m), Butyl Sepharose ® High Performance (average particle size: 90 ⁇ m), Phenyl Sepharose High Performance (average particle size: 90 ⁇ m), SOURCE 15ETH (average particle size: 15 ⁇ m), SOURCE 15ISO (average particle size: 15 ⁇ m), SOURCE 15PHE (average particle size: 15 ⁇ m), Capto Phenyl (High Sub) (average particle size: 90 ⁇ m), Capto
  • the average particle size of the chromatography media used for purification purposes in the present invention may be set to 15 ⁇ m or more, 20 ⁇ m or more, 30 ⁇ m or more, or 40 ⁇ m or more.
  • the volume of a crude antibody product which can be treated with the chromatography media may be set to 100 mL or more, 1 L or more, 10 L or more, or 100 L or more.
  • As a chromatography column to be filled with this media it is possible to use a chromatography column whose volume is 100 mL to around 1,000 L (diameter: 5 cm to around 2 m).
  • the volume of a crude antibody product provided for chromatographic purification is at least 1 L or more, desirably 10 L or more, more desirably 100 L or more, even more desirably 500 L or more, and up to around 20,000 L. Due to the necessity to treat such a large volume of a crude antibody product, the linear flow rate in chromatography is 1,000 cm/hr or less, and desirably 500 cm/hr or less.
  • the amount of antibody provided for purification is 10 g or more, desirably 100 g or more, more desirably 1 kg or more, and even more desirably 10 kg or more, calculated as the amount of protein.
  • Glycosylation isomers to be removed or reduced by this technique are contained in the first half fraction of antibody eluted by chromatography, and the desired antibody of interest is eluted into the second half fraction, whereby the glycosylation isomers are fractionated and removed.
  • Conditions under which a crude antibody product containing glycosylation isomers is loaded on conventional chromatography should at least be sufficient to allow a component of interest, i.e., an antibody having a sugar chain attached only to the glycosylation consensus region (non-glycosylation isomer antibody) to be adsorbed to the chromatography media.
  • a component of interest i.e., an antibody having a sugar chain attached only to the glycosylation consensus region (non-glycosylation isomer antibody)
  • Antibody adsorption is caused by interaction between the antibody and the chromatography media based on the degree of hydrophobicity-hydrophilicity.
  • a buffer it is possible to use a buffer commonly used in hydrophobic interaction chromatography, hydrophobic chromatography, or mixed-mode chromatography.
  • Any buffer may be used as long as the antibody is stable under chromatography conditions, and examples include phosphate buffer, acetate buffer, citrate buffer, Tris buffer, glycine buffer, borate buffer, tartrate buffer, MES buffer, HEPES buffer, MOPS buffer, amino acid buffer, and mixed buffers thereof.
  • concentration of these buffers may be selected freely within the commonly used range of around 0.1 mM to 300 mM.
  • the buffer pH may be selected freely within the range of pH 4 to 8, but it is preferably pH 4 to 6.
  • a salt such as sodium sulfate, ammonium sulfate, sodium chloride or sodium citrate may optionally be added in an appropriate amount not to cause antibody precipitation, thereby enhancing antibody interaction with the above chromatography media and thus allowing antibody adsorption to the chromatography media.
  • the above salt may be selected freely from one or more candidates.
  • the salt concentration antibodies are present stably in the range of 300 mM to 2 M salt, and the concentration used is required to allow sufficient antibody adsorption to the chromatography media.
  • the salt concentration is preferably around 1 M, and a lower salt concentration allowing antibody adsorption is preferred for this purpose.
  • the amount of antibody which can be adsorbed per unit amount of the chromatography media will widely vary depending on the type of the chromatography media and the conditions of the buffer, but 10 mg or more of antibody per mg of the media, preferably 20 mg or more of antibody per mg of the media can be adsorbed.
  • the chromatography may be operated at any temperature in the range of 0°C to 40°C.
  • the chromatography is desirably operated at room temperature, and more desirably operated under conditions where the temperature is controlled.
  • glycosylation isomers After the crude antibody product containing glycosylation isomers is loaded on chromatography under the conditions mentioned above, separation and purification are conducted by elution.
  • the separation of glycosylation isomers by chromatography may be accomplished as follows: after antibody adsorption to the chromatography media the buffer to be passed through the column is changed to reduce the salt concentration, increase the pH, reduce the conductivity, or combinations thereof, in a stepwise fashion, in a continuous fashion, or combinations thereof.
  • glycosylation isomers may first be eluted as a major faction, followed by eluting an antibody having a sugar chain attached only to the glycosylation consensus region (non-glycosylation isomer antibody) to thereby prepare a purified antibody composition of interest.
  • elution means that an antibody component bound to a chromatography media through hydrophobic interaction, etc., is treated to weaken its binding to the media, and the antibody component is released from the chromatography media.
  • the conditions required to elute glycosylation isomers are buffer conditions where the interaction between the glycosylation isomers and the chromatography media is sufficiently weaker than the interaction between the non-glycosylation isomer antibody and the chromatography media.
  • the chromatography media is washed with a sufficient volume of the buffer under these conditions, only the glycosylation isomers can be eluted and removed while ensuring that only the non-glycosylation isomer antibody, which is an antibody of interest, remains adsorbed to the chromatography media.
  • any buffer may be used to elute and remove (wash) the glycosylation isomers, as long as it has a 10 mM or more difference in salt concentration and/or a 0.2 Unit or more difference in pH from the buffer used to elute the non-glycosylation isomer antibody.
  • the salt concentration of the wash buffer used to wash the chromatography media may be set to be equal to or higher than the salt concentration for elution.
  • the salt concentration of the wash buffer may be equal to the salt concentration required for antibody elution or may range from equal to 1 M higher than the salt concentration required for antibody elution, or may range from equal to 0.5 M higher than the salt concentration required for antibody elution, or may be 10 mM or more higher than the salt concentration required for antibody elution, for example, may be set to 0.5 M or more or 1.0 M or more.
  • the pH of the wash buffer may be set to be equal to or up to 2 Units higher than the pH for antibody adsorption, or may be set to be equal to or up to 2 Units lower than the pH for antibody elution.
  • the pH of the wash buffer may be 0.2 Units lower than the pH of the eluent.
  • the pH of the wash buffer may be in the range of pH 4 to 8.
  • the passing volume of the buffer (wash buffer) required to elute and remove the glycosylation isomers may be set to 2 column volumes (CV) or more, 3 CV or more, 4 CV or more, 5 CV or more, 10 CV or more, 15 CV or more, or 20 CV or more, relative to the chromatography column volume, or may be set to 5 to 20 CV, 5 to 15 CV, 5 to 10 CV, or 10 to 20 CV, relative to the chromatography column volume.
  • the pH and/or salt concentration of the crude antibody product may be changed in a stepwise fashion (e.g., one or more steps, two or more steps, three or more steps, several steps) or in a continuous fashion.
  • the pH of the crude antibody product during the process from loading to washing is generally within the range of 4 to 6.
  • the conditions of the above salt concentration, pH and/or wash buffer volume may be determined as appropriate depending on the content of glycosylation isomers in the crude antibody product used as a starting material, and the properties of antibody per se including the isoelectric point and amino acid sequence, etc.
  • the chromatography-based method for separation of glycosylation isomers intended herein may comprise allowing the glycosylation isomers to flow through the chromatography media, and then eluting an antibody having a sugar chain attached only to the glycosylation consensus region, whereby a purified antibody composition containing the non-glycosylation isomer antibody with high purity can be prepared.
  • flow through means that when a crude antibody product is loaded on a column filled with a chromatography media, glycosylation isomers are eluted out from the column without being adsorbed to the chromatography media.
  • the glycosylation isomers in the crude antibody product may weakly interact with the chromatography media, but components containing these unwanted glycosylation isomers can be eliminated from the column by passing an equilibration buffer (desirably one or more column volumes) in a continuous or intermittent manner.
  • an equilibration buffer desirably one or more column volumes
  • a buffer is selected such that the interaction between the glycosylation isomers and the chromatography media is sufficiently weaker than the interaction between the antibody having a sugar chain linked only to the glycosylation consensus region and the chromatography media.
  • any buffer may be used as a wash buffer for flow through purposes as long as it has a 10 mM or more difference in salt concentration (i.e., a salt concentration of not less than 10 mM or higher) and/or a 0.2 Unit or more difference in pH (i.e., a pH of not less than 0.2 or lower) when compared to the eluent used to elute the antibody having a sugar chain linked only to the glycosylation consensus region.
  • the salt concentration of the buffer may be set to be equal to or up to 1 M higher (preferably up to 0.5 M higher) than the salt concentration required to elute the non-glycosylation isomer antibody from the media.
  • the salt concentration in this case is usually 100% or more relative to the salt concentration required for antibody elution.
  • the column is washed with a wash buffer whose pH is equal to or up to 2 Units higher than the pH for antibody adsorption or with a wash buffer whose pH is equal to or up to 2 Units lower than the pH for antibody elution.
  • the pH or/and salt concentration may be changed in a single step or several steps, or may be changed in a continuous fashion.
  • the salt concentration or pH of the buffer is usually adjusted within an appropriate range before the crude antibody product serving as a starting material is applied onto the chromatography media.
  • the passing volume of the buffer (wash buffer) required to allow the glycosylation isomers to flow through the column conditions are selected such that the passing volume is twice or more, desirably 5 times or more of the volume of the chromatography media.
  • the passing volume of the wash buffer is more desirably 10 to 20 times or more of the volume of the chromatography media.
  • the above salt concentration, pH or/and wash buffer volume may be determined as appropriate depending on the content of glycosylation isomers in the crude antibody product used as a starting material.
  • the protein load on the chromatography media affects the resolution of glycosylation isomers
  • the protein load per unit volume of the chromatography media is determined so as to achieve the desired yield and purity (glycosylation isomer content) in the resulting purified antibody composition.
  • the amount of protein which can be adsorbed to the media during chromatography operation so that the chromatography operation is controlled on the basis of parameters such as a maximum dynamic binding capacity (DBC).
  • DBC maximum dynamic binding capacity
  • a protein load below the maximum dynamic binding capacity provides good recovery and resolution of protein, and the desired separation effect of chromatography can be expected.
  • a protein load above a certain amount is preferred to avoid the adsorption of unwanted glycosylation isomers, and protein is loaded in an amount which is at least 20 mg or more, 25 mg or more, 30 mg or more, or 35 mg or more, per unit amount (1 g) of the chromatography media or per unit volume (1 mL) of the chromatography media, and is equal to or less than the maximum dynamic binding capacity, whereby the glycosylation isomers are separated and removed.
  • the protein load can be determined depending on the content of glycosylation isomers in the crude antibody product to be purified. Namely, if the content of glycosylation isomers is high in the crude antibody product before chromatographic purification, the protein load can be close to the maximum dynamic binding capacity.
  • the method of the present invention comprises the steps of selecting a conventional chromatography media to be used depending on the nature of antibody provided for separation, and optimizing the separation and removal of glycosylation isomers with the selected chromatography media.
  • the step of selecting a chromatography media may be accomplished as follows: a crude antibody product to be purified is first loaded on any two or more types of chromatography media under the above salt concentration and pH conditions to thereby select a chromatography media which adsorbs more antibody having a sugar chain attached only to the glycosylation consensus region.
  • these chromatography media may optionally be eluted with an eluent whose salt concentration is reduced in a stepwise or continuous fashion, and eluents passing through the media are each measured for the levels of glycosylation isomers and/or an antibody having a sugar chain attached only to the glycosylation consensus region, whereby a chromatography media giving an eluent with reduced levels of glycosylation isomers and rich in the antibody having a sugar chain attached only to the glycosylation consensus region may be selected as a chromatography media which is more excellent in the separation of glycosylation isomers.
  • conditions are considered and selected, including the composition, concentration and pH of a buffer used for loading, the type and concentration of a salt to be added, the amount of a crude antibody product loaded on the chromatography media, the composition, concentration and pH of a buffer used for washing, the frequency of washing and the volume of a wash buffer, the composition, concentration and pH of a buffer used for elution, the type and concentration of a salt to be added, and how to change them, and whether glycosylation isomers are removed by adsorption or flow through.
  • individual parameters may be optimized one by one, or alternatively, statistical analysis procedures such as the design of experiments may be used to select the optimal conditions including interactions among several parameters.
  • Techniques for antibody purification involve various steps. Most processes for antibody purification are conducted in two or more steps using different chromatography modes, but purification processes are usually often constructed using three steps of chromatography. For example, two or more of Protein A affinity chromatography, cation exchange chromatography, anion exchange chromatography, mixed-mode chromatography, hydrophobic interaction chromatography and so on are used in combination.
  • the method of the present invention may be integrated into any step of conventional chromatography in these antibody purification processes.
  • the method of the present invention may be used as hydrophobic interaction chromatography in the third step.
  • the method of the present invention may be used as hydrophobic interaction chromatography in the third step.
  • the method of the present invention may be used as hydrophobic interaction chromatography in the second step.
  • the method of the present invention may be used as hydrophobic interaction chromatography in the third step.
  • the method of the present invention may be used as a mixed-mode chromatography step in addition to hydrophobic interaction chromatography or in place of hydrophobic interaction chromatography.
  • the method of the present invention enables the efficient removal of glycosylation isomers and the provision of a purified antibody composition containing glycosylation isomers reduced to the desired content.
  • the ratio of glycosylation isomers relative to the total antibody in the purified antibody composition after purification can be 10% or less, more desirably 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, 0.5% or less, or 0.2% or less.
  • the ratio of glycosylation isomers relative to the total antibody in the crude antibody product before purification may be 50% or more, 20% or more, 10% or more, or 5% or more.
  • the method of the present invention may be a method for obtaining an antibody with reduced content of glycosylation isomers in a step yield of 20% or more, 40% or more, or 50% or more.
  • the content and ratio of glycosylation isomers and the purification yield in the final purified antibody composition or the antibody composition after purification may be achieved by adjusting the above chromatography parameters.
  • these parameters are optimized such that glycosylation isomers are reduced to any levels and a purification yield acceptable for antibody production is obtained.
  • glycosylation isomer removal may be confirmed by high-performance liquid chromatography (HPLC) or ultra-high performance liquid chromatography (UHPLC) for analysis and evaluation purposes.
  • HPLC high-performance liquid chromatography
  • UHPLC ultra-high performance liquid chromatography
  • a media with an average particle size of 15 ⁇ m or less is used, and glycosylation isomers can be separated by chromatography at ultra-high flow rate and at ultra-high pressure.
  • columns suitable for this purpose include a TSKgel Butyl-NPR column (average particle size: 2.5 ⁇ m, Tosoh Corporation, Japan), a TSKgel Phenyl-5PR column (average particle size: 10 or 13 ⁇ m, Tosoh Corporation, Japan), a TSKgel Ether-5PW column (average particle size: 10 ⁇ m, Tosoh Corporation, Japan), a TSKgel BioAssist Phenyl column (average particle size: 10 ⁇ m, Tosoh Corporation, Japan), a Protein-Pak Hi Res HIC column (Waters), a BioPro HIC column (average particle size: 2.3 or 4 ⁇ m, YMC Co., Ltd., Japan), a Proteomix HIC column (average particle size: 1.7 or 5 ⁇ m, M&S Instruments Inc., Japan), an AdvanceBio HIC column (average particle size: 3.5 ⁇ m, Agilent), an MAbPac HIC-10 LC column (average particle size: 5 ⁇ m,
  • the purified antibody composition thus purified by the method of the present invention can be used as an active ingredient of antibody drugs for use as therapeutic, prophylactic or diagnostic agents for various diseases in humans and animals.
  • the glycosylated antibody used was the humanized anti-human DLK-1 monoclonal antibody shown in WO2014/054820 having H and L chains (H chain: SEQ ID NO: 64, L chain: SEQ ID NO: 72 in the present application) (hereinafter referred to as "anti-hDLK-1 antibody").
  • This antibody has a glycosylation consensus sequence in the variable region of its light chain. For this reason, when animal cells or others are engineered to express this gene, there is a possibility that these cells will produce a sugar chain composition containing glycosylation isomers as a contaminant.
  • the CHO cell line DG44 was transformed with an expression vector carrying a gene encoding the amino acid sequence of the anti-hDLK-1 antibody to prepare a stable expression cell line pool, DGC8-R-T11-14.2d.
  • This cell line pool was used and cultured in a DASGIP ® Parallel Bioreactor System (Eppendorf) bioreactor on a 1 L scale.
  • the culture was conducted using a serum-free completely chemical synthetic medium by the fed-batch mode for 13 days under conditions of pH 7 and 34°C to 37°C.
  • This culture supernatant was purified by Protein A chromatography (with a MabSelect SuRe media (Cytiva)) to obtain an antibody composition.
  • the resulting antibody composition was subjected to HIC-HPLC analysis under the following conditions.
  • Peak 3 was an antibody having a sugar chain linked only to the glycosylation consensus region, while Peak 2 was deemed to be a glycosylation isomer having additional one sugar chain linked to the antibody of Peak 3, and Peak 1 was deemed to be a glycosylation isomer having additional two sugar chains linked to the antibody of Peak 3 (see Example 2).
  • This analysis result indicates that the crude antibody product obtained by culturing cells of the above pool was confirmed to contain about 10% of glycosylation isomers.
  • An expression vector (pFUSE) carrying gene sequences encoding the amino acid sequences of the heavy and light chains of the anti-hDLK-1 antibody, and an expression vector (pFUSE) encoding a mutant sequence (Asn-Ser-Ala) comprising a point mutation introduced into the third amino acid in the glycosylation consensus sequence (Asn-Ser-Ser) in the light chain of the anti-hDLK-1 antibody and encoding the amino acid sequence of the heavy chain of the anti-hDLK-1 antibody were each used to transform ExpiCHO cells to cause the transient expression of each antibody protein.
  • NSS antibody peptide-N-glycosidase F
  • SDS-PAGE SDS polyacrylamide gel electrophoresis
  • a culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers.
  • sodium chloride was added to give a final concentration of 1.0 M, and the crude antibody product was then adjusted to pH 5.0 and provided for use as a loading sample on a chromatography media.
  • Figure 3 shows an elution chromatogram (HIC 389). This result is indicative of antibody component adsorption to the Capto Butyl media under linear gradient conditions.
  • the loading sample on the column, the flow-through fraction from the Capto Butyl column, and the adsorption fraction to the same column were evaluated by HIC-HPLC analysis as shown in Example 1. The results obtained are shown in Figure 4 .
  • Glycosylation isomers contained at 2.1% (Peak 1) and 12.1% (Peak 2) in the loading sample were removed into the flow-through fraction (HIC 389 Flow-through), and a glycosylation isomer-free antibody composition of 100% purity (antibody having no sugar chains attached to sites other than the glycosylation consensus region) (Peak 3) was obtained in the column adsorption fraction (HIC 389 Elute).
  • glycosylation isomers can be separated by using a hydrophobic interaction chromatography media (Capto Butyl). It is indicated that upon use of the selected chromatography media, glycosylation isomers are efficiently removed into the flow-through fraction, and a high-purity purified antibody composition is obtained in the adsorption fraction.
  • a hydrophobic interaction chromatography media Capto Butyl
  • a culture supernatant containing the humanized anti-human DLK-1 monoclonal antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers.
  • sodium chloride was added to give a final concentration of 1.0 M, and the crude antibody product was then adjusted to have a pH of 4.5, 4.7 or 5.0 and a conductivity of 70 mS/cm or less and provided for use as a loading sample on a chromatography media.
  • peaks appearing around 0 to 50 mL in the horizontal axis are antibodies (glycosylation isomers) which were eluted by flowing through the column without being adsorbed, while an antibody eluted as a peak ranging from 50 to 300 mL indicates that an antibody having no sugar chains attached to sites other than the glycosylation consensus region is gradually eluted from the column.
  • antibody elution was observed throughout washing/elution, regardless of pH, thus indicating that the antibody having no sugar chains attached to sites other than the glycosylation consensus region can be obtained with high purity when collecting an intermediate layer of elution.
  • Capto Butyl and POROS Benzyl Ultra chromatography media were studied as to whether they were able to remove glycosylation isomers by stepwise elution.
  • the crude antibody product of Example 1 purified by Protein A affinity chromatography was adjusted with 0.5 M Tris to pH 4.5 or pH 5.0.
  • the salt concentration of a sample loading solution As parameters, the salt concentration of a sample loading solution, the pH and salt concentration of wash buffers (wash buffer I, wash buffer II), and the type and pH of an elution buffer were studied to measure the yield of antibody and the purity of non-glycosylation isomer antibody in the purified fraction (i.e., the purity of antibody having no sugar chains attached to sites other than the glycosylation consensus region) (the content of glycosylation isomers by HIC-HPLC analysis).
  • the test results obtained are shown in Table 3.
  • the purification yield with the Capto Butyl media under the respective conditions was 23% to 73%, and the purity of the purified antibody composition (antibody component free from glycosylation isomers) by HIC-HPLC analysis was 97.1% to 99.3%.
  • the purification yield with the POROS Benzyl Ultra media was slightly lower (33% to 67%), but the purity of the purified antibody composition by HIC-HPLC analysis was 100% under all the conditions.
  • the yield and the amount of glycosylation isomer contamination can be optimized in hydrophobic interaction chromatography media (e.g., Capto Butyl and POROS Benzyl Ultra) when optimizing the salt concentration and pH of a loading solution, the salt concentration and pH of a wash buffer, the volume of the wash buffer, the frequency of washing, the pH for elution and the type of buffer.
  • hydrophobic interaction chromatography media e.g., Capto Butyl and POROS Benzyl Ultra
  • a culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers.
  • sodium chloride was added to give a final concentration of 1.0 M, and the crude antibody product was then adjusted as appropriate for its pH and conductivity and provided for use as a loading sample on a chromatography media.
  • the load mass of the sample and the volumes of wash buffer I and wash buffer II were used as input parameters to evaluate the yield and the purity by HIC-HPLC analysis, which were output parameters.
  • the yield was able to be controlled to 40% to 80% with 97% to 100% purity when the protein load per unit volume of the chromatography media was adjusted to 25 g/L or more, and wash buffer I and wash buffer II were adjusted to 5 to 15 column volumes (CV) (Table 4).
  • the purity of the resulting purified antibody composition tended to be higher when the protein load was 30 g/L or 35 g/L than when the protein load was 25 g/L.
  • CV column volumes
  • this result indicates that when the protein load in chromatography is set to a certain value or higher and/or when the volume of each wash buffer is controlled appropriately, the content of glycosylation isomers can be reduced and controlled from about 10% to the range of 3% to 0%.
  • These results were analyzed by the design of experiment (DoE), and the results obtained are shown in Figure 6 .
  • the volumes of wash buffer I and wash buffer II and their effect on the yield and purity are expressed in contour chart form, thus indicating that any yield and purity can be controlled by the volumes of wash buffers.
  • a culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was purified by Protein A affinity chromatography to obtain a crude product of this antibody containing about 10% of glycosylation isomers.
  • This crude antibody product was kept at pH 3 to 4 for a certain period of time and neutralized for use as a loading sample on a chromatography media.
  • This crude antibody product was purified through the two flows shown in Figure 7 , i.e., purified sequentially by hydrophobic interaction chromatography and then mixed-mode chromatography, or sequentially by mixed-mode chromatography and then hydrophobic interaction chromatography.
  • the media used in hydrophobic interaction chromatography was POROS Benzyl Ultra, and the media used in mixed-mode chromatography was Capto MMC.
  • the conditions used for hydrophobic interaction chromatography are as shown below. For ID Nos. HIC 446, HIC 457 and HIC 463, hydrophobic chromatography was followed by mixed-mode chromatography. For ID No. HIC 447, mixed-mode chromatography was followed by hydrophobic chromatography.
  • the yield and purity of the purified antibody compositions obtained in the step of hydrophobic interaction chromatography are shown in Table 5 and Figure 8 .
  • the yield was 60% or more, and the purity by HIC-HPLC analysis (which represents the amount of glycosylation isomer contamination) was 99% or more.
  • the yield and purity were able to be controlled depending on the volume used in Washing 1 (6 to 15 CV). Namely, the composition with about 90% antibody purity was found to improve its purity to around 98% when washed with 5 CV, around 99% when washed with 8 CV, and around 99.5% when washed with 15 CV [Table 5] Results of the scale-up run of the HIC chromatography.
  • a culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was obtained in a volume of about 200 L.
  • the crude antibody product was confirmed to contain about 10% of glycosylation isomers.
  • the culture supernatant was filtered and then subjected to Protein A affinity chromatography (MabSelect SuRe 10 L; Cytiva), low pH viral inactivation, hydrophobic interaction chromatography with a POROS Benzyl Ultra media (Thermo Fisher, 10 L), mixed-mode chromatography with a Capto adhere media (Cytiva, 10 L), viral filtration, replacement with formulation buffer by tangential flow filtration (TFF), sterile filtration and other steps to obtain a high-purity purified antibody composition.
  • the purified antibody composition finally obtained through all the steps was obtained with a total yield of 46%. Moreover, the purity of the purified antibody composition by HIC-HPLC analysis was 100%, thus indicating that the purified antibody composition contained no glycosylation isomers. In this way, a purified antibody composition with sufficiently reduced levels of glycosylation isomers was able to be obtained even under chromatography conditions for antibody. Moreover, the protein load on the chromatography media was also shown to be important in the removal rate of glycosylation isomers.
  • a culture supernatant containing the anti-hDLK-1 antibody prepared in the same manner as shown in Example 1 was obtained.
  • the crude antibody product was confirmed to contain about 10% of glycosylation isomers.
  • a crude anti-hDLK-1 antibody product containing about 10% of glycosylation isomers obtained in the same manner as shown in Example 1 was precisely fractionated into individual peaks using the HIC-HPLC analysis system shown in Example 1. The fractionation was accomplished in about ten times, and fractions were combined for each peak, followed by buffer replacement with isotonic phosphate buffer. It should be noted that the HIC-HPLC mobile phase conditions used for fractionation were changed as shown below.
  • the present invention enables the preparation and use of a purified antibody composition with reduced levels of glycosylation isomers having sugar chains attached to sites other than the Fc region glycosylation consensus region.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22807406.8A 2021-05-10 2022-05-06 Procédé de purification d'une composition d'anticorps Pending EP4353734A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079977 2021-05-10
PCT/JP2022/019548 WO2022239704A1 (fr) 2021-05-10 2022-05-06 Procédé de purification d'une composition d'anticorps

Publications (1)

Publication Number Publication Date
EP4353734A1 true EP4353734A1 (fr) 2024-04-17

Family

ID=84029593

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22807406.8A Pending EP4353734A1 (fr) 2021-05-10 2022-05-06 Procédé de purification d'une composition d'anticorps

Country Status (9)

Country Link
EP (1) EP4353734A1 (fr)
JP (1) JPWO2022239704A1 (fr)
KR (1) KR20240005771A (fr)
CN (1) CN117279929A (fr)
AU (1) AU2022271741A1 (fr)
CA (1) CA3219950A1 (fr)
IL (1) IL308169A (fr)
TW (1) TW202309062A (fr)
WO (1) WO2022239704A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS644947A (en) 1987-06-29 1989-01-10 Rohm Co Ltd Consecutive recording method for video tape recorder
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
EP1739089A4 (fr) 2004-03-30 2007-05-02 Hiroshi Yanagisawa Procédé de séparation d'une protéine
JP4772905B2 (ja) 2007-04-02 2011-09-14 協和発酵キリン株式会社 アンチトロンビン組成物の製造方法
LT2905335T (lt) 2012-10-03 2018-04-10 Chiome Bioscience Inc. Antikūnas prieš žmogaus dlk-1, pasižymintis priešnavikiniu aktyvumu in vivo sąlygomis
EP3754012A1 (fr) * 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Purification d'anticorps et contrôle de pureté
CN113302197A (zh) * 2019-01-23 2021-08-24 第一三共株式会社 包括使用活性炭材料的工序的纯化抗体的方法
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
JP2021079977A (ja) 2019-11-19 2021-05-27 凸版印刷株式会社 袋状容器の注出口ユニット

Also Published As

Publication number Publication date
IL308169A (en) 2024-01-01
JPWO2022239704A1 (fr) 2022-11-17
AU2022271741A1 (en) 2023-11-23
WO2022239704A1 (fr) 2022-11-17
KR20240005771A (ko) 2024-01-12
CN117279929A (zh) 2023-12-22
TW202309062A (zh) 2023-03-01
CA3219950A1 (fr) 2022-11-17

Similar Documents

Publication Publication Date Title
US20190062419A1 (en) Protein purification methods to reduce acidic species
KR102380315B1 (ko) 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
AU2016333512B2 (en) Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US20230060770A1 (en) Cation exchange chromatography wash buffer
TR201808458T4 (tr) FC-reseptör bazlı afinite kromatografisi.
CA2766166A1 (fr) Conception de molecules fc d'anticorps exemptes d'agregation et stable par ingenierie de l'interface du domaine ch3
US20210355215A1 (en) Methods for purifying heterodimeric, multispecific antibodies
KR102390246B1 (ko) 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
JP6850351B2 (ja) 抗体のインビトロ糖鎖工学
JP6952115B2 (ja) 抗体のインビトロ糖鎖工学のための方法
KR102578087B1 (ko) 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
US20240115701A1 (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability
EP4353734A1 (fr) Procédé de purification d'une composition d'anticorps
US20150361128A1 (en) Methods of using ion exchange chromatography to control levels of high mannose glycoforms
JPWO2020061478A5 (fr)
JP2023545019A (ja) タンパク質精製プロセスにおいて宿主細胞タンパク質含有量を減少させるための方法
Jung et al. Mass Production of Full‐Length IgG Monoclonal Antibodies from Mammalian, Yeast, and Bacterial Hosts

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR